Corpus ID: 77199763

St. John's wort warning: do not combine with protease inhibitors, NNRTIs.

  title={St. John's wort warning: do not combine with protease inhibitors, NNRTIs.},
  author={James Js},
  journal={AIDS treatment news},
  • James Js
  • Published 2000
  • Medicine
  • AIDS treatment news
: St. John's wort, an herbal treatment for depression, should not be combined with certain drugs, including some antiretrovirals. St. John's wort can speed up the body's elimination of some drugs. When HIV medications are used, blood levels could drop low enough to allow resistance to occur. So far, St. John's wort has been tested only with the protease inhibitor indinavir (Crixivan), but it is likely to affect other drugs in that class and possibly non-nucleoside reverse transcriptase… Expand
Clinical use of St. John's Wort: Drug-drug interaction potential of marketed products and challenges for drug development
It is best to avoid the use of SJW if the risk of treatment failure is highly likely, but a window of opportunity exists where the dose of the respective medicinal agent may be increased to achieve the desired clinical outcome when comedicated with SJW, if such a dose increment does not pose a safety risk or a compliance issue to the patients. Expand
Effect of Herbal Medicines on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Subjects
Two clinical studies conducted as part of this research found that warfarin has an important role in treating people with heart disease, yet it has a narrow therapeutic range, is highly bound to plasma proteins, and is metabolised by cytochrome P450, which creates the potential for life-threatening interactions with other drugs and foods leading to excessive bleeding. Expand
Managing issues related to antiretroviral therapy.
Antiretroviral regimens are complicated and difficult for patients to follow, and they can have serious side effects, such as osteonecrosis and bone demineralization. Protease inhibitor therapy hasExpand
Reasons for complementary therapies and characteristics of users among HIV-infected people
The most common expectations from CT were to improve energy and to prevent or alleviate the HAART side effects, which suggests that HIV-infected people expect not so much specific help as general support from CT. Expand
Protecting the Public from Snake Oils and Magic Soups
Recently, a man posing as a physician was sentenced to prison for bilking more than $300,000 from 18 patients with cancer who had trusted his judgment. He had convinced them to buy his purported cureExpand
Highly active antiretroviral therapy and the kidney: an update on antiretroviral medications for nephrologists.
  • J. Berns, N. Kasbekar
  • Medicine
  • Clinical journal of the American Society of Nephrology : CJASN
  • 2006
The clinical pharmacology and dosing modifications of the newer antiretroviral medications in patients with reduced kidney function; important drug-drug interactions involving these medications, particularly with other medications that are likely to be prescribed by nephrologists; and renal toxicities of antireTroviral agents are reviewed. Expand
Medicinal-Induced Behavior Disorders.
An approach to the patient with central nervous system toxicity, depending on presentation of sedation versus agitation and accompanying physical signs and symptoms is explored. Expand
The Development of Herbal Medicinal Products
Over time, the development process for herbal medicinal products should become more closely aligned with the development of new chemical entities, and ethnopharmacology and knowledge provided by existing clinical trials is a source of invaluable insight into the safety and efficacy of herbal remedies. Expand
Dietary Supplement Interaction With Nutrients
The retail sales (in food stores, drug stores, mass market outlets) for herbal supplements in 2002 totaled more than $300 million out of pocket in the United States (1). Sales are much greater inExpand
Human immunodeficiency virus and depression in primary care: a clinical review.
The clinical presentation and differential diagnosis of depressive symptoms in HIV illness and the role of HIV in the development of these conditions are reviewed, and potentially important pharmacokinetic interactions are reviewed. Expand